The Origin of Allosteric Functional Modulation: Multiple Pre-existing Pathways  by del Sol, Antonio et al.
Structure
ReviewThe Origin of Allosteric Functional Modulation:
Multiple Pre-existing Pathways
Antonio del Sol,1 Chung-Jung Tsai,2 Buyong Ma,2 and Ruth Nussinov2,3,*
1Bioinformatics Research Unit, Research and Development Division, Fujirebio Inc., 51 Komiya-cho, Hachioji-shi, Tokyo 192-0031, Japan
2Basic Research Program, SAIC-Frederick, Inc., Center for Cancer Research Nanobiology Program, NCI-Frederick, Frederick,
MD 21702, USA
3Sackler Institute of Molecular Medicine, Department of Human Genetics and Molecular Medicine, Sackler School of Medicine,
Tel Aviv University, Tel Aviv 69978, Israel
*Correspondence: ruthnu@helix.nih.gov
DOI 10.1016/j.str.2009.06.008
Although allostery draws increasing attention, not much is known about allosteric mechanisms. Here we
argue that in all proteins, allosteric signals transmit throughmultiple, pre-existing pathways; which pathways
dominate depend on protein topologies, specific binding events, covalent modifications, and cellular (envi-
ronmental) conditions. Further, perturbation events at any site on the protein surface (or in the interior) will not
create new pathways but only shift the pre-existing ensemble of pathways. Drugs binding at different sites
or mutational events in disease shift the ensemble toward the same conformations; however, the relative
populations of the different states will change. Consequently the observed functional, conformational, and
dynamic effectswill be different. This is the origin of allosteric functionalmodulation in dynamic proteins: allo-
stery does not necessarily need to invoke conformational rearrangements to control protein activity and
pre-existing pathways are always defaulted to during allostery regardless of the stimulant and perturbation
site in the protein.Proteins are the ‘‘workhorses’’ of the cell. Their response to
changes in the cellular environment is modulated by an effector.
The effector perturbs one site and thereby leads to an altered
activity in a second, substrate site. Allostery is regulation at
a distance by conveying the information from the first site to
the second. Allostery is relayed through the cellular membrane,
the cytoplasm and into the nucleus amplifying signaling (Ma
and Nussinov, 2009) and the signals are sent dynamically
(Smock and Gierasch, 2009). Allostery can result from physical
binding events (with proteins, DNA/RNA, small molecules,
lipids); light, as the photoswitch LOV2-Ja illustrates, fluctuating
between ‘‘dark’’ inactive and ‘‘light’’ active conformations (Yao
et al., 2008); mutational events; covalent modifications (phos-
phorylation, glycosylation, tethering (Hardy et al., 2004); or
changes in the environment (pH, temperature, ionic strength,
etc.). Allostery was originally described in oligomeric systems
(Changeux and Edelstein, 2005). Two recent reviews (Cui and
Karplus, 2008; Goodey and Benkovic, 2008) provide a historical
perspective: the first highlights cooperativity; the second
emphasizes that catalysis and allostery emerge via common
communication routes. Key questions include comprehensive
description of allosteric mechanisms (Tsai et al., 2009), predic-
tion of allosteric sites whether on the protein surface or of
residues whose mutation (Liu and Nussinov, 2008) could lead
to allosteric effects, the pathways through which signals travel,
and allosteric drug discovery. Currently, observation of specific
pathways experimentally is a challenging problem. However,
nuclear magnetic resonance (NMR) provides information on
protein dynamics from which pathways can conceivably be in-
ferred (Boehr et al., 2006; Kern and Zuiderweg, 2003; Swain
and Gierasch, 2006; Volkman et al., 2001). Recently, by using
NMR relaxation dispersion techniques, the dynamic process1042 Structure 17, August 12, 2009 ª2009 Elsevier Ltd All rights resthrough which the KIX domain of CREB binding protein commu-
nicates allosteric information was directly observed (Bruschweiler
et al., 2009), revealing that information is transmitted through an
evolutionarily conserved network of residues. Computationally,
strategies for pathway identification have been proposed (del
Sol et al., 2006, 2007; Chennubhotla and Bahar, 2006). Below,
we first briefly describe the principles of allostery, the ‘‘old’’
view, the so-called new view and an updated new view (Tsai
et al., 2008). The ‘‘updated new’’ view leads us to re-address
some of these questions. In particular, it highlights an allosteric
property that has largely been overlooked: allostery invariably
involves multiple pathways. Multiple pathways can relate to muta-
tional effects in disease; to modulation in signaling pathways and
to drug discovery. However, key to allostery, regardless of the site
and nature of the perturbation events, propagation will take place
via the same pathways. The different perturbation events will
simply shift pre-existing populations. This is the origin of allosteric
modulation in cellular pathways and in drug-binding effects.
The Old View, the New View, and the Updated New View
An Emerging Definition Based on Pure Thermodynamic
Terms
Over the years, static pictures of allosterically regulated proteins
indicated a change in the shape of the substrate binding site
between the On/Off states depending on whether the effector
molecule was bound at the allosteric site. This has led to the
paradigm that allostery involves conformational change. The
two classical models, the Monod-Wyman-Changeux (or, MWC
for short) (Monod et al., 1965) and the Koshland-Nemethy-Filmer
(KNF) (Koshland et al., 1966), described allostery as a binding
event at one site altering protein activity via a conformational
change at the second site. The MWC model (Monod et al., 1965)erved
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Figure 1. The TwoCritical Differences between theOld andUpdated
New View
In allostery, perturbation at the effector site causes some activity change at the
substrate site. The allosteric stimulus and activity change are illustrated as
binding events.
(A) The old view: An effector binds and causes an active site conformational
change via a single propagation pathway, making an unfavorable substrate
binding become favorable.
(B and C) The two basic differences between the old and the updated new
view. First, due to the nature of the thermodynamic equilibrium, the updated
new view is based on population shift, and does not endorse the kinetic
concept of propagating and releasing the strain energy created at the allosteric
site via a single pathway; rather, it postulates that population shift from an off-
state to an on-state (or vice-versa) must involve multiple pathways through
network interactions. Panel B presents the multiple propagation pathways
with an active site conformational change. Only pathways relating to such
conformational change are shown. In panel (C), no conformational change is
associated with the population shift; here, allostery is entropy dominated.
Thermodynamically, population shift with an accompanied conformational
change could be dominated by enthalpy or entropy; however, a free energy
change without conformational change is entropy dominated. In the case of
allostery with enthalpy-dominated conformational change, all propagation
pathways effectively lead to the required conformational change. In positive
cooperativity, the unfavorable active site conformation becomes substrate
favorable. The opposite holds for negative cooperativity. For the case of
entropy-dominated conformational change, consider an effector binding to
disordered structure. This is positive cooperativity with entropy loss (disorder
becomes order) prepaid by effector binding. Prepaid entropy via backbone
and side-chain rigidification would be a case of entropy-dominated positive
cooperativity without conformational change. In negative cooperativity without
conformational change, effector binding enhances the dynamics; subsequent
substrate-induced rigidification creates extra, nonadditive entropy loss. AboveStructuemphasized that the conformational transition is a concerted
action between two coexisting, distinct states (relaxed and
tense, or R and T); the KNF model (Koshland et al., 1966) formu-
lated it as a sequential, induced conformational change by the
binding at the first site. The classical old view rested on two
assumptions: that there are two distinct conformations and in
the absence of a ligand their ratio is governed by the equilibrium
constant; and that allostery involves a change of shape. In
contrast to the old view, the more recent new view recognized
that the native states are ensembles of pre-existing populations;
thus, an allosteric effector leads to an equilibrium shift of
pre-existing conformational and dynamic states (Gunasekaran
et al., 2004). Now, the updated new view posits that allostery
does not necessarily even involve a change of shape (Tsai
et al., 2008). Recent data (Daily and Gray, 2007; Popovych
et al., 2006; Tsai et al., 2008) validate the theoretical proposition
(Cooper and Dryden, 1984), indicating that even if there is no
visual change in the shape of the backbone at the substrate
binding site upon binding of the allosteric effector, there could
still be an allosteric change in the substrate binding site, and in
protein activity. Popovych et al. (2006) presented direct experi-
mental evidence illustrating that allostery can be mediated solely
by changes in protein dynamics without any conformational
change. Daily and Gray assembled an allosteric protein bench-
mark of pairs of known inactive and active allosteric protein
structures from the Protein Data Bank (PDB) (Berman et al.,
2002). The data set includes structural pairs with no or subtle
conformational change, governed largely by entropy (Daily and
Gray, 2007). This absence of conformational change leads to
a definition of allostery in pure thermodynamic terms: allostery
can be controlled by enthalpy; by enthalpy and entropy; or solely
by entropy (Tsai et al., 2008, 2009). This updated new view is
important because it helps in understanding allosteric mecha-
nisms and thus in prediction of allosteric sites, allostery-related
residues, allosteric drugs, and allosteric modulation.
Allostery Involves Multiple Pathways between
the Perturbation and the Substrate Binding Sites
and Dynamic Transitions
The old view defined allostery in terms of two discrete states. It
sought a single, well-defined propagation pathway between
the allosteric- and substrate-binding sites that would lead to
a conformational change. All allosteric residues were on this
pathway and the signals were assumed to be transmitted by
mechanically forming and breaking noncovalent interactions
between on-pathway residues (Figure 1A). The old view was
unable to offer an explanation for disease-causing (or, prevent-
ing [Trible et al., 2007]) mutations that were not at the binding
sites, retained the global protein conformation, and did not lie
on that pathway. In contrast, in the new view (Figures 1B and
1C) it is not a specific propagation pathway but an ensemble
of states (Gunasekaran et al., 2004) that is the key for allostery;
thus multiple pathways, major and minor, between the allosteric
and the substrate binding sites. At the allosteric site noncovalent
binding, covalent modification such as tethering, phosphoryla-
tion, or a point mutation create local stress. Local stress perturbs
we focus on enthalpy- or entropy-dominated allostery; not a combination of
both (Tsai et al., 2008). The realization of these two critical differences impacts
the understanding and prediction of the allosteric effects.re 17, August 12, 2009 ª2009 Elsevier Ltd All rights reserved 1043
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Figure 2. Examples of Proteins with Experimental Data Supporting
the Existence of Multiple Pathways for Allosteric Communications
(A) Two possible pathways for allosteric communications upon RA-GEF2
peptide binding mapped onto the structure of PDZ2-RA-GEF2 (PDB code:
1D5G), with the RA-GEF2 peptide shown in yellow. In red are represented resi-
dues energetically coupled to His71 (Lockless and Ranganathan, 1999). The
black line depicts a pathway formed by these residues that starts at the
peptide binding site residue His71 and splits into two subpathways that end
at two residues located at the opposite side of the domain (A46 and V85).
An alternative pathway composed of residues whose side-chain dynamics
significantly change upon peptide binding (shown in blue) is represented
with the white line (Fuentes et al., 2004). This pathway also starts at a peptide
binding site residue (V26) and splits into two subpathways ending at two resi-
dues (A39 and T81) belonging to two distal surfaces from the peptide binding
site (Fuentes et al., 2004), correspondingly. Distal surface 1 is composed of
Thr81, Val85, Val61, Val64, Leu66, and Leu69, whereas distance surface 2
contains Ala39 and Val40. Residues shown in brown are common to both path-
ways.
(B) Two alternative possible pathways for the transmission of perturbation
upon ligand binding (MLL) on the structure of the complex KIX-MLL-c-Myb
(PDB code: 2AGH). In red are residues that experience structural changes
upon MLL binding (Bruschweiler et al., 2009). The black line depicts a pathway
formed by these residues, which starts at the MLL binding site and ends at the
c-Myb binding site. The yellow and pink helices correspond to MLL and c-Myb
ligands, respectively. Residues colored in blue, which exhibit significant back-
bone chemical shift changes upon MLL binding (Goto et al., 2002), form
a hydrophobic groove that links the MLL binding site with a distinct protein
surface. This surface might be a novel binding site for other ligands. Residue
F612 shown in brown is common to both networks of residues.1044 Structure 17, August 12, 2009 ª2009 Elsevier Ltd All rights resethe structure, and the perturbation propagates via multiple path-
ways from the allosteric to the substrate binding sites. The PDZ2
domain interacts with a C-terminal peptide ligand obtained from
the Ras-associated guanine nucleotide exchange factor 2 (RA-
GEF2). It is known that binding site histidine 71 (hPTP1E PDZ2
numbering) determines the PDZ2 specificity, defining PDZ2 as
class I PDZ domain (Kozlov et al., 2002). For the PDZ domain
family, Ranganathan and coworkers predicted and confirmed
experimentally a set of energetically coupled positions for the
binding site residue His71. In Figure 2A, this set of residues
has been mapped onto the PDZ2/RA-GEF2 structure, forming
a pathway that starts at the RA-GEF2 binding site and ends on
the opposite side of the domain. Side-chain methyl dynamics
measurements on the PDZ2 domain showed that allosteric
transmissions due to RA-GEF2 peptide binding might be domi-
nated by side-chain dynamics (Fuentes et al., 2004). Residues
whose side-chain dynamics changed significantly upon peptide
binding are also illustrated in Figure 2A. These residues form an
alternative pathway starting at the peptide binding site and
ending at two distal surface regions from the peptide binding
site (see legend to Figure 2). These two pathways share common
residues belonging to the protein core and distal surface 1.
These findings based on the PDZ domain suggest the existence
of multiple pathways from the perturbation to the substrate
binding sites. The KIX domain of the CREB binding protein
CBP provides another example of an allosteric protein with
experimental data supporting the presence of multiple allosteric
communication pathways. The KIX domain binds the mixed
lineage leukemia transcription factor (MLL) inducing binding of
the activation domain from c-Myb (Goto et al., 2002). Recently,
using NMR relaxation measurements, a pathway through which
the allosteric information is transmitted upon MLL binding was
observed (Bruschweiler et al., 2009). This pathway, which is
formed by hydrophobic amino acids experiencing significant
structural rearrangements, proceeds from the MLL binding site
toward the c-Myb binding site (Figure 2B). Interestingly, a previous
NMR study identified a set of residues exhibiting significant back-
bone amide chemical shift changes upon MLL binding (Goto et al.,
2002).These amino acids forma hydrophobic groove thatcontains
MLL binding site residues and other solvent exposed residues
belonging to a distinct protein surface and are possibly involved
inbinding ofother ligands (Figure2B). Thus, in thisexample,exper-
imental results suggest the existence of two pathways that trans-
mit the information to different protein surface patches.
An allosteric network has also been recently detected in cas-
pase 1 (Datta et al., 2008). Of particular interest, 21 hydrogen
bonds from nine side chains belonging to this network which
connects the active and the allosteric sites were observed to
alternate between the on-state and the off-state. Alanine-scan-
ning mutagenesis of these side chains has shown that only two
of these (Arg286 and Glu390), which form a salt bridge, have
major effects on catalysis, reducing it by 100- to 200-fold. Two
neighboring residues, Ser332 and Ser339, have minor effects,
causing 4- to 7-fold reductions, suggesting that the salt-bridging
residues are on the major allosteric pathway, whereas the neigh-
boring residues might reside on a minor communication pathway
(Figure 3). Further, even a homologous substitution of the salt-
bridging residue R286K causes a large 150-fold reduction. The
structures of these variants suggest that in addition to salt bridgerved
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Reviewformation, these residues play an important role in the coordina-
tion of solvent water molecules near the allosteric binding
pocket. A critical salt bridge important for specificity in discrim-
inating between binding partners has also been detected in p160
coactivator ACTR (Demarest et al., 2002). Computationally,
major and minor pathways have been detected in the tRNA
synthetases (Sethi et al., 2009) and in the pVHL protein (Liu
and Nussinov, 2008).
Although not formulated in allosteric terms, Ansari et al. (1985)
pointed out that similar to an earthquake, stress released from
the focus could dissipate through propagation of deformation,
and in the form of waves. From the theoretical standpoint, as
in protein folding and in earthquake, in protein allostery a realistic
scenario involves preferred pathways under given conditions. In
principle, which pathway dominates can be determined from
mutational effects: a mutation with a significant effect lies on a
major pathway; a minor effect suggests a minor pathway. Muta-
tions can break native state interactions and make new interac-
tions (Figure 3). Although mutational effects can be assessed by
the extent of the allosterically-related conformational change,
this is not necessarily the case. The perturbation caused by
the effector could be reflected solely in entropy changes with
no observable conformational change (Tsai et al., 2008), as illus-
trated by Popovych et al. (2006) and in structural comparisons of
different allosteric states (Daily and Gray, 2007) (Figure 1C). The
changes in entropy reflect all pathways under given conditions;
that is, the landscape. Further, the new view is based on pre-ex-
isting equilibrium, invoking transitions between protein confor-
mational and dynamical states (Formaneck et al., 2006; Kumar
et al., 2000; Ma et al., 1999, 2002). Thus, key allosteric residues,
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Figure 3. A Schematic Two-Dimensional
Lattice Chain Illustrating Allosteric
Pathways
The figure depicts a 15-residue chain with red bars
indicating its backbone trace. Each residue is also
given two exact interactions with its neighbors
either via side chain-side chain or side chain-
backbone interaction. The long brown bar indi-
cates a strong interaction and short blue bar
stands for a weak interaction. A micropathway is
drawn starting from the perturbation site down to
the second (substrate) site via the residue-residue
interaction linkage (8/7/6/5/13). A muta-
tion at residue 10 will not alter the allosteric effect
because not a single residue-residue interaction
has been changed.
predicted via coupling between residue
pairs quantified by statistical coupling
energies (Suel et al., 2003) or experimen-
tally identified by double mutant cycles
(Horovitz and Fersht, 1990), are not only
those lying on the communication paths
(Horovitz and Fersht, 1992; Sadovsky
and Yifrach, 2007) but also those impor-
tant for conformational and dynamical
transitions. Mutations affecting these
transitions could get the protein trapped,
hindering population shift. Topologically,
protein structures can be computation-
ally decomposed into energetically independent modules, the
building blocks of protein domains (del Sol et al., 2006, 2007;
Hu et al., 2007). Intermodular residues play a key role in signal
transmission. These residues are rigid, sustaining key amino
acid interactions for the communication between modules (del
Sol et al., 2006, 2007). Most of the intermodular residue interac-
tions form long-range contacts that are predominantly involved
in mediating signaling. Multiple pathways between the perturba-
tion- and the substrate-binding sites are likely to share such
central residues, but to diverge in modules. Further, recently,
comparisons of crystal structures of the inactive and active
forms of protein pairs led to identification of ‘rigid bodies’ (Daily
and Gray, 2009). Analysis of the interactions between these
showed that they are cyclically connected, again associating
protein motions with network organization. Thus, multiple path-
ways always exist even if undetected by experiment; they can
be reflected in dynamics and in conformational changes. The
question is whether they encode different functions. Currently,
no such cases are known, probably because it is only a matter
of the relative concentration of the populations thus not suffi-
ciently robust and sensitive to conditions.
What Is a Pathway?
Above, we related to pathways through which the signal is
communicated between sites. A pathway implies a specific
sequence in time and space. A pathway consists of a set of resi-
dues that are in (dynamic) contact. Allosteric pathways in a
protein can be visualized as strain energy, created by a perturba-
tion at the effector’s site, radiating out to ease the unbalanced
energy through residue-residue interactions (Figure 3). Theoret-
ically, in terms of such a description, allosteric pathways are theStructure 17, August 12, 2009 ª2009 Elsevier Ltd All rights reserved 1045
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Here we define a micropathway as a specific linkage starting
from a residue at the perturbation site that follows a specified
residue-residue interaction path down to a residue at the second
(substrate) binding site. If the weightings for all residue-residue
interactions in a protein are known, a statistical evaluation of
the frequency for each residue to be on the pathway that con-
ducts the allosteric wave from the effector’s site to the second
(substrate) site can be computed through a complete enumera-
tion of all micro-pathways. In our definition, the pre-existing
(major and minor) pathways are the outcome of a visualization
of the linkage based on selected residues with a high statistical
frequency above certain scale. The caspase-1 functional ‘‘hot
wire’’ or ‘‘allosteric circuit’’ (Datta et al., 2008) provides an excel-
lent experimental example for major and minor pathways de-
tected via mutagenesis studies illustrating our point.
What Are Protein Conformational
and Dynamical States?
Above, we further related to protein conformational and dynam-
ical states. A conformational state is determined by its associ-
ated free energy. For example, a binding event at the allosteric
site shifts the population of the unbound (conformational) state
to a bound (conformational) state. It is determined purely by ther-
modynamics. The change at the substrate site, however, is
determined dynamically via residue-residue interactions to
release the created strain energy if there is a conformational
change at the allosteric site. If, however, there is no conforma-
tional change at the allosteric site, the stiffness (i.e., loss of
entropy) will still propagate dynamically through residue-residue
interactions down to the substrate site.
There Are Not One but Multiple Allosteric Perturbation
Sites
Above, signal transmission occurred between two sites: the
effector and the substrate. This situation rarely occurs in vivo.
In the cell, all dynamic proteins have more than a single effector
perturbation site. Proteins generally function when in large
assemblies, and when regulated by multiple coincident environ-
mental changes, binding or modification events. Let us consider
the following multiple co-occurring perturbation scenarios: (i)
only two molecules bind; however, external conditions change;
(ii) disease-related mutations occurred, as for example in the
pVHL, which still needs to bind its substrate and partner proteins
(Knauth et al., 2006); (iii) there are more than two binding sites, as
in tumor suppressor protein p53 (Riley et al., 2008); pVHL (Ohh
et al., 2000); or regulatory proteins in the ubiquitin ligase E3
complex (Hao et al., 2007); (iv) there are multiple modification
sites in the protein, for example phosphorylation sites on the
p53 (Riley et al., 2008), or acetylation (Luo et al., 2004); (v)
enzymes or receptors that recognize a large number of
substrates, such as the kinase which must recognize between
one and a few hundred phosphorylation sites, while at the
same time discriminating an order of magnitude more potential
phosphorylation sites in the kinome (Ubersax and Ferrell, 2007),
arguing for possible allosteric modulating effectors; (vi) dynami-
cally coregulated proteins that have to respond to complex cell
signals (Komurov and White, 2007); (vii) and finally, binding sites
shared by different proteins (Keskin and Nussinov, 2007; Tunc-
bag et al., 2009). The conformations and dynamic effects of these1046 Structure 17, August 12, 2009 ª2009 Elsevier Ltd All rights resare condition (i.e., perturbation) dependent. Clearly, each phos-
phorylation, mutational, covalent ubiquitination, nucleotide-
binding, or change in the environment is a perturbation event.
Signaling proteins constitute examples of combinations of
such events. They are multimodular and the transmission of
information can involve several mechanisms such as posttrans-
lational modification, assembly into complexes, changes in
subcellular distribution, enzymatic activity, and multiple binding
events. Because mechanisms generally co-occur, they all
present multiple perturbation events. Socs suppressors of cyto-
kine signaling (Yoshimura et al., 2007) provide one example of
a system subject to different mechanisms (Bullock et al.,
2007). Socs proteins are induced by cytokines acting in a nega-
tive-feedback loop to inhibit cytokine signal transduction; they
are also induced by various stimuli, such as lipopolysaccharide,
isoproterenol, statins, and cyclic AMP, suggesting multiple inter-
actions in different environments with various protein/small
molecule partners. The Socs proteins form part of the E3 ligase
machine tagging proteins for degradation. The Socs box domain
binds to the adaptor proteins, elongin C and elongin B, and the
substrate binding domain binds to the substrate. Socs also
undergoes post-translational modifications. All these events
perturb the structure, enhancing allosteric effects. A second
example relates to the molecular chaperones in the assembly
of cellular complexes (Morimoto, 2002). Molecular chaperones
respond to hormones and stress, and different combinations
govern the activities of intracellular hormone receptors and
heat shock transcription factors. Molecular chaperones dynam-
ically ensure tight control, and rapid reversible transcriptional
response. Thus their functional roles implicate complex interac-
tions and multiple allosteric perturbation sites. A third example is
provided by the 14-3-3 proteins. This conserved regulatory
family modulates the action of target proteins by sequestration,
relocalization, and conformational changes. They bind signaling
proteins including kinases, phosphatases, transmembrane
receptors, enzymes, and structural and cytoskeletal proteins
and are involved in metabolic pathways, redox-regulation, tran-
scription, RNA processing, protein synthesis, protein folding and
degradation, cell cycle, cytoskeletal organization, and cellular
trafficking (Kjarland et al., 2006). Thus, in vivo, for all (dynamic)
proteins, the strain energy created at each of the many perturba-
tion sites radiates out propagating and merging similar to waves
initiating at several perturbed locations, to enhance, dissipate, or
alter the features of the deformation reaching the target site.
Experiment is unable to directly observe specific propagation
routes. However, because the relative pathway utilization varies,
there are different observable allosteric effects that can be
inferred from functional expression. Examples include the home-
odomain-interacting protein kinase 2 (HIPK2) (Sombroek and
Hofmann, 2009), which depending on the phosphorylation state
activates the apoptotic program by engaging diverse down-
stream targets, including tumor suppressor p53 and the antia-
poptotic transcriptional corepressor C-terminal binding protein.
For the p53, specific posttranslational phosphorylation events
are well documented to regulate its functions (Kruse and Gu,
2009). An additional example concerns Mdm2. Mdm2 is a nega-
tive regulator of p53. p53 promotes the transcription of Mdm2; in
turn, Mdm2 binds to p53 and stimulates the ubiquitination of the
p53 carboxy terminus, marking it for degradation. Mdm2 alsoerved
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tory growth function. pRb interacts with the transactivation
domain of the E2F family transcription factors, and blocks E2F
dependent transcription. The Mdm2 interaction with pRb
disrupts pRb-E2F binding, leading to an increase in the E2F-
dependent transcription (Martin et al., 1995). The stabilization
of the E2F1 protein reflects another p53-independent compo-
nent of Mdm2-mediated tumorigenesis via direct Mdm2-E2F1
interaction (Zhang et al., 2005). Mdm2 further interacts with
PCAF, which competes with E1A for binding sites on P300/
CBP (Jin et al., 2002). PCAF also provides a good example:
PCAF has separate acetyltransferase and E3 ubiquitin ligase
domains and a bromodomain for interaction with other proteins.
In addition, it also possesses sites for its own acetylation and
ubiquitination (Linares et al., 2007). Hence, to conclude, each
binding and each posttranslational modification (like phosphory-
lation or acetylation) event alters the relative pathway utilization.
Consequently, the ensuing binding events to other proteins
might be altered, leading to (some) functional modifications.
This alteration in the relative pathway utilization in a given
protein—which can be enhanced or suppressed by other pertur-
bation event(s)—is the origin of allosteric modulation in all
dynamic proteins.
Scaffolding Proteins Are Not Inert Either
Although scaffolding proteins lead to colocalization and thus
amplification and higher efficiency of signal transfer, they are
not passive; they apparently also modulate the interactions of
particular signaling modules. Thus, even the seemingly ‘‘inert’’
proteins, whose role was originally believed to bring other
proteins together for them to interact, have highly complex regu-
latory functions requiring allosteric multisite communication.
Scaffold proteins are involved in processes such as intracellular
trafficking and pathway sequestering, and several factors have
been shown to influence their signaling function (Kolch, 2005).
Mmitogen-activated protein kinase (MAPK) scaffolds were sug-
gested to hold the kinases in a manner that directly enhances
their mutual interactions, thus potentially enhancing the rate of
the phosphate transfer. At the same time, the MAPK-pathway
‘‘scaffold’’ prototype is not a passive docking site for multiple
kinases. Ste5 is a yeast protein involved in the Fus3 MAPK
pathway (Burack and Shaw, 2000). Shuttling of the Ste5 complex
through the nucleus is required for maintenance of pathway
constituents in a state competent to participate in signaling:
Ste5 that is unable to transit the nucleus cannot localize at the
periphery and is unable to activate the pathway. However,
Ste5 transiting the nucleus is able to localize and activate the
pathway (Mahanty et al., 1999). Although currently there are no
direct amplification data for the scaffolding proteins, studies of
Ste5 revealed multistep, multicomponent, multi-binding-site
scaffolding proteins that can allow fine-tuned regulation (Burack
and Shaw, 2000). The ubiquity of these multileveled kinase
cascades allows not only signaling amplification but also incor-
porates regulatory checkpoints (Kolch, 2005). Hence, the coloc-
alization, amplification, and the multiple interactions of the scaf-
folding proteins argue for multiple perturbation sites. The
different times, combinations, and complex formation of these
proteins inherently implies function modulated by multiple allo-
steric pathways originating at these perturbation sites and prop-
agating like waves to the substrate binding sites.StructThe MAPK signaling pathway involves successive activation of
three kinases, MAPKKK, MAPKK, and MAPK. MAPKKK acti-
vates MAPKK, which in turn activates MAPK. Ste5 has separate
binding sites for each. Just now, in a fascinating work, Good
et al. (2009) showed that Ste5 is indeed an allosteric activator
of the mitogen-activated MAPK (Fus3) (see also the Perspective
by Seeliger and Kuriyan, 2009). In its inactive state, Fus3 exists
in a ‘‘locked,’’ MAPKK binding-incompatible conformation,
with an inaccessible phosphorylation site. However, the Ste5
domain (Ste5ms) binding transforms Fus3 to a binding-compat-
ible conformation with an accessible phosphorylation site.
Examples of Allosteric Modulation, Allosteric Drugs,
and Small Molecules
Multiple pathways can be seen in allosteric modulators like
hormones and neurotransmitters whose signals are recognized,
amplified, and transmitted. A hormone is released into the blood-
stream; a neurotransmitter is released from a nerve terminal
following an electrical impulse in direct apposition to its target
cells to ensure rapid and specific delivery of the signal. Allosteric
modulators enhance the signals; they do not compete with
endogenous ligands and therefore can exert their influence
even if an endogenous ligand is bound to another site on the
same target. Allosteric modulators contrast orthosteric allosteric
effectors that compete with endogenous ligands for the same
site on a given target. Allosteric modulators are not limited to
simply turning a receptor on or off; rather, they offer a control
over the degree of activation or deactivation like a light dimmer
switch. Small molecule drugs can mimic this effect by inducing
allosteric activation (Conn et al., 2009; Kalatskaya et al., 2009;
Kenakin, 2007; Langmead and Christopoulos, 2006; Pelkey
et al., 2007). Modulating allosteric drugs can have a nonobserv-
able activity in the absence of endogenous ligands; as such, they
offer a less disruptive way to influence the functioning of biolog-
ical systems. Because on their own the perturbation they cause
is small, they better preserve the regulation of cellular processes
compared to orthosteric (same site) approaches. Targeting allo-
steric binding sites represents a powerful mechanism for selec-
tively modulating receptor function. Such modulators enhance
(or reduce) ‘‘traffic’’ in innate propagation pathways.
The seven-transmembrane (7TM) receptors are the largest,
most ubiquitous and versatile membrane receptor family; they
also constitute the most common drug targets. The N terminal
is outside; the C terminal inside the cell. Binding of small extra-
cellular ligands shifts the ensemble from a resting to an activated
state driving signal transduction pathways and cellular re-
sponses. Orthosteric interaction obstructs access of endoge-
nous ligands; allosteric binding usually occurs away from this
site. Both can be associated with conformational (or dynamical)
change. The M(2) muscarinic receptor provides a specific recent
example: it has two distinct sites, orthosteric and allosteric. The
allosteric site is recognized by compounds such as gallamine.
Muscarinic receptors form oligomers resulting in two or more or-
thosteric and allosteric sites per multimer, an arrangement allow-
ing cooperative interaction. Redka et al. (Kenakin, 2007; Redka
et al., 2008) have shown that orthosteric ligands like N-methyl
scopolamine and oxotremorine-M bind to the allosteric site of
the M(2) muscarinic cholinergic receptor although at higher
concentrations. The allosteric effects of orthosteric compounds
like N-methyl scopolamine and oxotremorine-M mimic theure 17, August 12, 2009 ª2009 Elsevier Ltd All rights reserved 1047
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can contribute to conformational or dynamical events assumed
to initiate at the orthosteric site, and suggesting coincidence of
some propagation pathways. Of particular interest is that allo-
stery was detected by the propensity of 7TM receptors to form
dimers, thus demonstrating allosteric effects through binding
at the orthosteric site. Thus, in principle, any part of the protein
can be an allosteric site, and the thermodynamic outcome of
the binding might be to bias the ensemble to a similar pharmaco-
logically relevant endpoint. The binding of a ligand at either site,
orthosteric or allosteric, stabilizes a preferred conformational
state.
Although frequently modulating drugs enhance the activity,
Quiniou et al. (2008) have recently obtained a negative allosteric
peptide regulator of IL-1, a major proinflammatory cytokine that
interacts with the IL-1 receptor I (IL-1RI) complex. Another inter-
esting recent case is that of the orthosteric agonist neurokinin A
(NKA). NKA interacts with the tachykinin NK2 receptors (NK2Rs),
stabilizing the receptor in at least two different active conforma-
tions (A1L and A2L). A small molecule, LPI805, is a noncompeti-
tive inhibitor of NKA binding to NK2Rs, which decreases the
number of NKA-NK2R complexes in A2L conformation and
increases those in A1L conformation. Analysis of signaling path-
ways of NK2Rs showed that LPI805 dramatically inhibits the
NKA-induced cAMP response while slightly enhancing the
NKA-induced calcium response, establishing that allosteric
modulators can be used to promote functional selectivity (Maillet
et al., 2007). Another high-profile, impressively potent drug,
Gleevec, is an example of an allosteric inhibitor that alters protein
kinase conformation to block productive ATP binding (Bogoye-
vitch and Fairlie, 2007). Because Gleevec does not bind at the
conserved ATP-binding site and as such does not compete
with ATP binding, it has fewer side effects. Gleevec binds to
the inactive conformational state, shifting the equilibrium in this
(inactive) direction (Formaneck et al., 2006; Kumar et al., 2000;
Ma et al., 1999, 2002; Tsai et al., 1999). Finally, a small molecule,
InsP6 (inositol hexakisphosphate) was recently shown to induce
allosteric activation of a toxin Vibrio cholerae RTX (Repeats in
Toxin). RTX is an actin-disrupting toxin that is autocleaved by
an internal cysteine protease domain (CPD). The autocleavage
is activated by InsP6, which binds to a conserved basic cleft,
distant from the protease active site. CPD mutants indicate
that InsP6 binding induces an allosteric change, leading to the
autoprocessing and intracellular release of toxin-effector
domains (Lupardus et al., 2008).
Conclusions
Here we argue that allostery involves multiple pathways, and that
all pathways between all allosteric and all substrate binding sites
pre-exist. As in protein folding, under any set of (cellular or
in vitro) conditions, there will be major pathways and minor path-
ways. We posit that allosteric events at different sites will shift the
ensemble; but they will not create new pathways. That is, we
argue that all allosteric perturbation events such as binding of
small molecules or other proteins on the protein surface or muta-
tional or posttranslational events occurring anywhere in the
protein structure will only lead to a shift in the relative populations
of the different states. The shift in the ensemble can lead to
different observed conformational, dynamic, and functional1048 Structure 17, August 12, 2009 ª2009 Elsevier Ltd All rights reseffects. That is, all pathways are already there; it is only a ques-
tion of the population shift and which pathways dominate.
Allosteric perturbation creates stress. The strain energy
created at the perturbation sites dissipates by radiating out,
propagating and merging similar to waves initiating at several
perturbed locations, merging to enhance, dissipate or alter the
features of the deformation reaching target sites. This is the
origin of allosteric modulation in all dynamic proteins. Further,
allosteric perturbation at a newly discovered allosteric site will
not lead to new conformational or dynamical states; it will
however disrupt, enhance, or modulate substrate binding.
Thus, allosteric modulators are not limited to simply turning
a receptor on or off; rather, they offer a control over the degree
of functional activation or deactivation, like a light dimmer
switch. Allosteric effectors, including allosteric drugs, mimic
this effect.
Such a scheme rationalizes allosteric functional modulation; it
explains why binding at different sites will lead to similar func-
tional effects, except with different relative populations. Here,
we provided a range of experimental examples substantiating
such a theoretical proposition. We further note that the pathways
form networks, and the networks have a modular organization
with the modules connected via central residues.
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